Total trials
2,133
Active
223
Phase 3
736
Total enrollment
2,984,317
Pipeline matrix
Showing 40 of 265 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Sotatercept | — | — | 13 | ||||
| Background PAH Therapy | — | — | — | — | 3 | ||
| Pembrolizumab | — | 239 | |||||
| Paclitaxel | — | — | 65 | ||||
| Carboplatin | — | — | 70 | ||||
| Sacituzumab tirumotecan | — | — | — | 26 | |||
| Cisplatin | — | — | — | 56 | |||
| Belzutifan | — | — | — | 23 | |||
| Pemetrexed | — | — | — | 35 | |||
| Rescue medication | — | — | — | 22 | |||
| Lenvatinib | — | — | — | 45 | |||
| Docetaxel | — | — | — | 31 | |||
| Nab-paclitaxel | — | — | — | 19 | |||
| Gemcitabine | — | — | — | 26 | |||
| Rescue Medications | — | — | — | 10 | |||
| Dexamethasone | — | — | 29 | ||||
| Cyclophosphamide | — | — | — | 16 | |||
| Oxaliplatin | — | — | — | 18 | |||
| Calderasib | — | — | — | 13 | |||
| Intismeran autogene | — | — | — | — | 9 | ||
| Capecitabine | — | — | — | — | 24 | ||
| Prednisone | — | — | — | 19 | |||
| Cetuximab | — | — | — | 16 | |||
| Nemtabrutinib | — | — | — | 15 | |||
| Bevacizumab | — | — | — | 14 | |||
| Doxorubicin | — | — | — | 12 | |||
| Rituximab | — | — | — | 8 | |||
| Zilovertamab vedotin | — | — | — | — | 8 | ||
| Pembrolizumab (+) Berahyaluronidase alfa | — | — | — | 8 | |||
| Patritumab deruxtecan | — | — | — | — | 7 | ||
| Supportive care measures | — | — | — | 7 | |||
| Olaparib | — | — | — | — | 14 | ||
| Etoposide | — | — | — | 11 | |||
| Leucovorin | — | — | — | 11 | |||
| Acetaminophen | — | — | — | 10 | |||
| Ifinatamab Deruxtecan | — | — | — | — | 6 | ||
| MK-8527 | — | — | — | 15 | |||
| 5-fluorouracil | — | — | — | 10 | |||
| Pembrolizumab/Quavonlimab | — | — | — | — | 9 | ||
| 9vHPV vaccine | — | — | — | — | — | 9 |
225 more active programs hidden
Next readouts
- 2018-01-08
- 2021-06-21
- 2023-02-10
- 2023-04-04
- 2023-07-10
- 2024-04-15
- 2024-06-04
- 2024-07-12
- 2024-07-25
- 2024-10-10
Top conditions
- Healthy109
- Type 2 Diabetes Mellitus108
- Hepatitis C, Chronic77
- Hepatitis C62
- HIV Infections57
- Diabetes Mellitus, Type 229
- Hypertension29
- Pneumococcal Infections27
Frequently asked questions about Merck Sharp & Dohme LLC
- How many clinical trials does Merck Sharp & Dohme LLC have on ClinicalTrials.gov?
- Merck Sharp & Dohme LLC is listed as the lead sponsor on 2,133 clinical trials in ClinicalTrials.gov, 223 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Merck Sharp & Dohme LLC's trials are in Phase 3?
- 736 of Merck Sharp & Dohme LLC's trials are in Phase 3, spread across 265 active drug programs.
- What therapeutic areas does Merck Sharp & Dohme LLC focus on?
- Merck Sharp & Dohme LLC's most-studied conditions on ClinicalTrials.gov are Healthy, Type 2 Diabetes Mellitus, Hepatitis C, Chronic, Hepatitis C, HIV Infections.
- When are Merck Sharp & Dohme LLC's next clinical trial readouts?
- Merck Sharp & Dohme LLC has 10 upcoming primary-completion readouts tracked here; the soonest is “Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)”, expected around 2018-01-08.